Clinical Trial of the Week: Treatment study for older patients with advanced non-small lung cancer

By Donna Loyle, communications manager, LIMR


Researchers seek to determine if there are any side effects of Keytruda® (pembrolizumab) with or without chemotherapy in treating patients aged 70 and older diagnosed with metastatic, stage 4 non-small cell lung cancer.


Eligible participants are grouped into two study arms:

  • Group A receives pembrolizumab IV on day 1. Cycles repeat every 21 or 42 days.
  • Group B receives pembrolizumab and the chemotherapies pemetrexed and carboplatin IV on day 1. Cycles for pembrolizumab repeat every 21 or 42 days. Cycles for the chemotherapies repeat every 21 days.


Study # A171901 is approved for all MLH acute care hospitals. For more on this clinical trial, email or visit

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Your email address will not be published.